Remicade (Infliximab) Dosing and Frequency
The standard dosing for Remicade is 5 mg/kg administered intravenously at weeks 0,2, and 6 for induction, followed by maintenance infusions of 5 mg/kg every 8 weeks thereafter. 1
Standard Dosing Regimen
Induction Phase
- 5 mg/kg IV infusion at weeks 0,2, and 6
- Administered over 2-3 hours 2, 3
- This three-dose induction achieves clinical response in approximately 80% of patients by week 10 2
Maintenance Phase
- 5 mg/kg IV infusion every 8 weeks 1, 3
- For ankylosing spondylitis specifically: every 6 weeks 1
- Regular scheduled maintenance is superior to as-needed dosing for preventing loss of response 4
Dose Optimization Strategies
For Loss of Response
When patients initially respond but subsequently lose therapeutic effect:
- Increase dose to 10 mg/kg every 8 weeks, OR
- Shorten interval to every 4 weeks at 5 mg/kg 1
- Doubling the dose (10 mg/kg every 8 weeks) is generally more convenient and cost-effective than interval shortening 5
Important caveat: Higher doses and more frequent dosing increase the risk of serious infections 1. This risk must be weighed against therapeutic benefit.
Therapeutic Drug Monitoring Guidance
For secondary loss of response, measure serum drug levels and anti-drug antibodies to guide decisions 5:
- Low drug levels + no antibodies: Increase dose or shorten interval
- Adequate drug levels (>3.8 μg/mL) OR high antibodies (>9 μg/mL equivalent): Switch to alternative therapy
- Target trough levels of 8-10 μg/mL in remission 6
Disease-Specific Considerations
Rheumatoid Arthritis
- 3 mg/kg at weeks 0,2, and 6, then every 8 weeks 1
- Must be combined with methotrexate 1
- Can escalate to 10 mg/kg every 8 weeks or every 4 weeks if incomplete response
Pediatric Patients (≥6 years)
- 5 mg/kg at weeks 0,2, and 6, then every 8 weeks 1
- Same dosing for both Crohn's disease and ulcerative colitis
Critical Practice Points
Combination Therapy
Concomitant immunomodulator therapy (particularly methotrexate or thiopurines) for the first 6-12 months reduces antibody formation and improves long-term efficacy 7. However, this must be balanced against increased lymphoma risk, particularly hepatosplenic T-cell lymphoma in young males with IBD 1.
Assessment Timeline
- Evaluate primary efficacy after the second or third dose 6
- Discontinue if no significant response by week 14 1—patients unlikely to respond with continued dosing
Maintenance Strategy
Continuous scheduled maintenance therapy is superior to episodic "as-needed" dosing 2, 4. Once significant disease relapse occurs, repeat infusions may not achieve the same clearance rate as initial induction 4.
Infusion Reactions
Occur in up to 20% of patients 4. Management:
- Mild-to-moderate: Slow or temporarily stop infusion; give antihistamines, hydrocortisone, acetaminophen
- Severe: Discontinue infusion permanently
- Premedication is not routinely required but may be considered 6
Mandatory Pre-Treatment Screening
- Tuberculosis testing (PPD or interferon-gamma release assay) is obligatory before initiating therapy 6, 1
- Evaluate for active tuberculosis and test for latent infection periodically during therapy 1
Common Pitfalls to Avoid
- Switching to as-needed dosing after initial response—this increases risk of antibody development and treatment failure 4
- Continuing therapy beyond week 14 without response—these patients are unlikely to benefit 1
- Empirically changing doses without checking drug levels—TDM can prevent unnecessary switches and optimize existing therapy 5
- Using infliximab >5 mg/kg in patients with NYHA Class III/IV heart failure—this is contraindicated 2